<Media xmlns:cdr="cips.nci.nih.gov/cdr" Usage="External">
  <MediaTitle>pertuzumab, trastuzumab, and hyaluronidase-Spanish</MediaTitle>
  <PhysicalMedia>
    <SoundData>
      <SoundType>Speech</SoundType>
      <SoundEncoding>MP3</SoundEncoding>
      <RunSeconds>4</RunSeconds>
    </SoundData>
  </PhysicalMedia>
  <MediaSource>
    <OriginalSource>
      <Creator>Vanessa Richardson, VR Voice</Creator>
      <DateCreated>2021-05-26</DateCreated>
      <SourceFilename>Week_2021_16_Rev1/801883_es_rr.mp3</SourceFilename>
    </OriginalSource>
  </MediaSource>
  <MediaContent>
    <Categories>
      <Category>pronunciation</Category>
    </Categories>
    <ContentDescriptions>
      <ContentDescription audience="Patients" language="es">Pronunciation of dictionary term "pertuzumab y trastuzumab con hialuronidasa"</ContentDescription>
    </ContentDescriptions>
  </MediaContent>
  <ProposedUse>
    <Glossary cdr:ref="CDR0000801883">pertuzumab, trastuzumab, and hyaluronidase;pertuzumab y trastuzumab con hialuronidasa pertuzumab, trastuzumab y hialuronidasa [es]</Glossary>
  </ProposedUse>
<ProcessingStatuses><ProcessingStatus><ProcessingStatusValue>Processing Complete</ProcessingStatusValue><ProcessingStatusDate>2021-05-26</ProcessingStatusDate><EnteredBy>oseipokuw</EnteredBy></ProcessingStatus><ProcessingStatus><ProcessingStatusValue>Audio re-recording approved</ProcessingStatusValue><ProcessingStatusDate>2021-05-26</ProcessingStatusDate><EnteredBy>oseipokuw</EnteredBy></ProcessingStatus></ProcessingStatuses></Media>